# REPORTING OF ADVERSE REACTIONS AND PRODUCT QUALITY COMPLAINTS

## HEADER

|Item          |Details|
|--------------|---------| 
|Purpose       |Describing the process and responsibilities to collect Adverse reactions (ARs) reports and Product Quality Complaints (PQCs)      |
|Department    |Quality and PV |
|Category     |GDP         |

## REFERENCES AND ASSOCIATED DOCUMENTS

### References

* [Directive 2010/84/EU amending directive 2001/83/EC][Directive 2010/84/EU]
* [Regulation EU No 1235/2010 amending regulation EC 726/2004][Regulation EU No 1235/2010]
* [Good Pharmacovigilance Practices (GVP) Module I, ll and VI][GVP Guidelines]
* [Customer Complaints][ZIWKI]

## DEFINITIONS AND ACRONYMS/ABBREVIATIONS

### Definitions

*Adverse reaction (AR)*

Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

*Special case scenario*

* ARs associated with a suspected or confirmed falsified medicinal Product(s) or with a product quality complaint.
* ARs due to drug to drug or food to drug interaction.
* The following speciai situations, with *or* without an associated AR:
  * exposure during pregnancy and/or breastfeeding
  * possible exposure to embryos or foetuses via mother or semen (via conception for substances with a long half—life)
  * overdose
  * abuse
  * misuse
  * off label use
  * medication error
  * lack of efficacy {excluding for clinical studies)
  * transmission of an infectious agent via the Product 
  * occupational exposure
  * unexpected benefit

*Product Quality Complaint (PQC)*

A complaint which may indicate any possible, including actual, failure of a drug product to meet any of its specifications designed to ensure that any drug products conform to appropriate standards of safety, efﬁcacy, identity, strength quality, purity and package integrity and durability.

*Medical Information Enquiry (MIE)*

Request of medical information from healthcare professional (HCP) patients, caregivers, relatives, members or self-aid groups sales representatives, press media, authorities etc.

*First level Support*

MIE which can be answered by using the approved product information. First contact point for any MIE.

*Second level Support*

MIE which can be answered by using published or internal information besides approved product information.

## ROLES

Role | Description | Who
--- | --- | --- 
Receiver | Person who receives a report. | Any staff


## PROCEDURE

AR reports are handled by PV, PQC are handled by Quality. 

All spontaneous AR report and PQC made to staff are forwarded to the appropriate function. All intents to report an AR or make a PQC should be deferred to the appropriate function. Staff should forward any communication received, and communicate contact details of the tentative reporter, in order for the appropriate function to follow-up.


## TRAINING

All permanent and outsourced staff must read and understand this procedure.

[GMP Guidelines]: https://ec.europa.eu/health/documents/eudralex/vol-4_en]
[GDP Guidelines]: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:343:0001:0014:EN:PDF
[GVP Guidelines]: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf
[Directive 2010/84/EU]: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf
[Regulation EU No 1235/2010]: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32010R1235
[AMXWS]: /procedures/Procedure_GDP_AMXWS_Management_of_Standard_Operating_Procedures.md
[XIDEX]: /procedures/Procedure_GDP_XIDEX_Responsible_Person.md
[BWRPX]: /procedures/Procedure_GDP_BWRPX_Documentation_Control.md
[XCEUG]: /procedures/Procedure_GDP_XCEUG_Deviations.md
[UYNEF]: /procedures/Procedure_GDP_UYNEF_Change_Control.md
[OZCFN]: /procedures/Procedure_GDP_OZCFN_Management_Review_And_Monitoring.md
[LBHIY]: /procedures/Procedure_GDP_LBHIY_Quality_Risk_Management.md
[ZWJPR]: /procedures/Procedure_GDP_ZWJPR_Training.md
[VQICE]: /procedures/Procedure_GDP_VQICE_Receipt_Of_Medicinal_Products.md
[AGTXC]: /procedures/Procedure_GDP_AGTXC_Establishing_The_Authority_Of_Suppliers_To_Supply_Medicinal_Products.md
[ZIWKI]: /procedures/Procedure_GDP_ZIWKI_Customer_Complaints.md
[VOZWP]: /procedures/Procedure_GDP_VOZWP_Recall_Procedure.md
[HBQIN]: /procedures/Procedure_GDP_HBQIN_Outsourced_Activities.md
[GMQHI]: /procedures/Procedure_GDP_GMQHI_Self_Inspections.md
[VTOMR]: /procedures/Procedure_GDP_VTOMR_Falsified_Medicinal_Products.md
[BMAXZ]: /procedures/Procedure_GDP_BMAXZ_Medicinal_Product_Returns.md
[YUISV]: /procedures/Procedure_GDP_YUISV_CAPA.md
[QEAIC]: /procedures/Document_QEAIC_Glossary.md
[GGNHM]: /procedures/Procedure_GDP_GGNHM_Reporting_of_Adverse_Events.md
